Introduction:Sarcopenia, a condition characterized by a loss of skeletal muscle mass, is increasingly recognized as a significant factor influencing patient outcomes in pancreatic cancer (PC). This systematic review and meta-analysis aimed to estimate the prevalence of sarcopenia in patients with PC using computed tomography and to explore how different measurement methods and cut-off values impact such prevalence.Materials and Methods:Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a comprehensive search of PubMed, Web of Science, and EMBASE databases was performed, identifying 48 observational studies involving 9063 patients.Results:The overall pooled prevalence of sarcopenia was 45% (95% CI, 40–50%), but varied significantly by the method used: 47% when measured with the skeletal muscle index and 33% when assessed with the total psoas area. In addition, in studies using SMI, sarcopenia prevalence was 19%, 45%, and 57% for cutoff values <40 cm2/m2, 40–50 cm2/m2, and >50 cm2/m2, respectively. Moreover, the prevalence was higher in patients receiving palliative care (50%) compared to those treated with curative intent (41%). High heterogeneity was observed across all analyses, underscoring the need for standardized criteria in sarcopenia assessment.Conclusions:Our findings highlight the substantial variability in sarcopenia prevalence, which could influence patient outcomes, and stress the importance of consensus in measurement techniques to improve clinical decision making and research comparability.
引言：肌肉减少症是一种以骨骼肌质量减少为特征的病症，在胰腺癌患者预后影响因素中日益受到重视。本系统性综述与荟萃分析旨在通过计算机断层扫描评估胰腺癌患者中肌肉减少症的患病率，并探讨不同测量方法和界值如何影响该患病率。 材料与方法：遵循系统综述和荟萃分析优先报告条目指南，对PubMed、Web of Science和EMBASE数据库进行全面检索，共纳入48项观察性研究，涉及9063例患者。 结果：肌肉减少症的总体汇总患病率为45%（95%置信区间：40%-50%），但随测量方法不同呈现显著差异：采用骨骼肌指数测量时为47%，而采用总腰大肌面积评估时为33%。此外，在使用骨骼肌指数的研究中，当界值分别设定为<40 cm²/m²、40-50 cm²/m²和>50 cm²/m²时，肌肉减少症患病率依次为19%、45%和57%。值得注意的是，接受姑息治疗患者的患病率（50%）高于接受根治性治疗的患者（41%。所有分析均观察到高度异质性，这凸显了建立肌肉减少症评估标准化标准的必要性。 结论：本研究结果揭示了肌肉减少症患病率存在显著差异，这种差异可能影响患者预后，并强调了在测量技术上达成共识的重要性，以提升临床决策的科学性和研究结果的可比性。
肿瘤(癌症)患者之家